ClinicalTrials.gg
RecruitingNCT07016126Updated Oct 26, 2026

D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

A Phase 2 interventional study of D-BACE in combination with chemotherapy and karelizumab in NSCLC (Non-small Cell Lung Cancer), sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Guangdong Provincial People's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.
Updated Oct 26, 2026Enrollment updatedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Provincial People's Hospital — 9 open to participants now, 12 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Guangdong Provincial People's Hospital.

Planned enrollment
5th of 13
46 · median 45
Started
2024
with 2 others
Phase 2
11 of 18
5 open now
Primary completion
2027-12
later than 8 of 11 live
Registered
15th of 18
by date

Among the 18 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Provincial People's Hospital, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 18 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Provincial People's Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Provincial People's Hospital, or all of them as a file.
02

Study summary

This study is a single-arm prospective single-center phase II study. Subjects are untreated resectable stage II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC. Forty-six subjects will be enrolled in this prospective observation, using a Simon two-stage optimal design, aimed at evaluating the clinical efficacy and safety of D-BACE in combination with neoadjuvant chemotherapy and camrelizumab in patients with resectable stage II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC. The primary endpoint is the major pathological response (MPR) rate, defined as no more than 10% residual viable tumor cells in the primary tumor bed upon comprehensive pathological assessment. The treatment group regimen will be 3 cycles of D-BACE (DCB drug-eluting microspheres loaded with epirubicin 50 mg) in combination with chemotherapy and camrelizumab (the specific regimen of chemotherapy will be determined by the investigator, and platinum-based doublet chemotherapy will generally be used). Adverse events will be monitored throughout the trial and graded for severity according to NCI CTCAE version 5.0. Tissue and blood specimens will be dynamically collected during the course of treatment for translational research.

Read the detailed description

This study is a single-arm prospective single-center phase II study. Forty-six patients with untreated resectable stage II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC will be included in this prospective study, using a Simon two-stage optimal design. The aim of this study is to evaluate the major pathological response (MPR) rate and safety of D-BACE combined with neoadjuvant chemotherapy and camrelizumab in patients with resectable stage II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC. MPR is defined as no more than 10% residual viable tumor cells in the primary tumor bed upon comprehensive pathological assessment. The treatment regimen is 3 cycles of D-BACE (epirubicin 50 mg loaded on DCB microspheres) combined with chemotherapy and camrelizumab (the specific chemotherapy regimen is determined by the investigator, and generally platinum-based doublet chemotherapy is used, such as pemetrexed [500 mg/m²] plus carboplatin [AUC=5] for non-squamous carcinoma, or albumin-bound paclitaxel [260 mg/m²] plus carboplatin [AUC=5]). Adverse events will be monitored throughout the trial and their severity will be graded according to the NCI CTCAE, version 5.0. At the same time, tissue and blood samples will be dynamically collected during the treatment for related translational research exploration.

Patients could discontinue the regimen if:

  • Having comorbidities that significantly affect the assessment of clinical status or require discontinuation of protocol treatment (investigator's discretion);
  • Unacceptable treatment toxicity;
  • Disease recurrence or new primary invasive malignancy;
  • At patient's request.

4.1 Screening

Subjects will complete whole-body PET-CT and contrast-enhanced brain MR before enrollment to determine stage II-IIIB NSCLC. Patients are required to obtain adequate tissue or cell pathological diagnosis, relevant immunohistochemistry, PD-L1 protein immunohistochemistry and NGS testing before enrollment. At the same time, peripheral blood will be collected before treatment for exploratory clinical research. Tumor tissue is provided in newly obtained formalin-fixed specimens (preferred) or in old formalin-fixed paraffin-embedded specimens from sites not irradiated prior to biopsy. Tumor tissue must be archived before treatment (tissue blocks, slides ≤6 months old, or recently fresh tumor biopsy slides submitted to the local study center). PD-L1 status is determined as follows:

PD-L1 positive: defined as ≥1% tumor cell membrane staining positive in at least 100 evaluable tumor cells.

PD-L1 negative: defined as \<1% tumor cell membrane staining positive in at least 100 evaluable tumor cells.

PD-L1 nonevaluable/ambiguous: defined as subjects with insufficient sample quantity or quality to determine PD-L1 status by staining, or subjects with adequate tissue sample but still unable to determine PD-L1 status, who are classified together with PD-L1-negative subjects.

Screening (baseline) assessments are to be performed within 28 days before the first D-BACE.

4.2 Neoadjuvant therapy: D-BACE should be administered within 28 days of baseline screening, adopting the "watershed vascular embolization" concept. This concept defines the complete blood supply unit nourishing the lesion as the "watershed vessel," emphasizing that the therapeutic target should shift from embolizing a single vessel to managing the entire dynamic blood supply network. It is a lesion-centered, universal interventional concept that, after completing structural anatomical assessment and functional blood supply analysis, achieves layered and zonal embolization of feeding arteries in the core and peripheral watersheds to reshape the hemodynamic balance of the lesion, thereby improving treatment thoroughness, safety, and long-term efficacy.

Specific operative steps:

One vial of 300-500 μm DC Bead is loaded with 50 mg epirubicin. After full drug loading, 10-20 mL of non-ionic contrast agent is added. Under digital subtraction angiography (DSA) monitoring, femoral artery puncture is performed according to the Seldinger technique. Combined with preoperative CTA assessment of the thoracic watershed vessels supplying the tumor, the systemic circulation blood supply includes four sub-watersheds (cervical, thoracic, axillary, and abdominal regions). Cobra, MIK, single-curve, or similar angiographic catheters are used to explore the openings of tumor-feeding arteries in each sub-watershed and perform angiography to understand the distribution of feeding arteries and tumor vasculature. Microcatheter superselective cannulation into the tumor-feeding artery is recommended. During angiography, embolization, and post-embolization, the dynamic balance concept of "watershed vascular embolization" is emphasized. If systemic artery-to-pulmonary artery/pulmonary vein shunting is observed during angiography, blank microspheres, PVA, or microcoils may be used first to occlude the shunt tract. After angiography, blood supply analysis is performed, followed by layered and zonal embolization of feeding arteries in the core and peripheral watersheds. After confirming avoidance of the spinal artery, drug-loaded microspheres are injected into the tumor-feeding artery through the microcatheter for chemoembolization at a rate of 1 mL/min. Antegrade blood flow in the target embolized vessel must be maintained. If "near-stasis" is observed during injection (i.e., the columnar contrast material in the vessel disappears after 2-5 heartbeats), injection must be stopped regardless of the actual amount of microspheres injected, to avoid reflux of the embolic agent. Conversely, if "near-stasis" does not occur after the full target dose is infused, no additional embolic agents are administered. After completing embolization of all target vessels, repeat angiography of the main arterial trunk in the embolized region is performed for watershed boundary confirmation and endpoint determination. After the procedure, the arterial catheter and sheath are removed, the arterial puncture site is compressed and bandaged, and the hip joint is immobilized for more than 6 hours.

Neoadjuvant chemotherapy and camrelizumab should be administered within 7 days after D-BACE. The chemotherapy regimen is determined by the investigator, generally platinum-based doublet chemotherapy, such as pemetrexed (500 mg/m²) plus carboplatin (AUC=5) (non-squamous carcinoma), or albumin-bound paclitaxel (260 mg/m²) combined with carboplatin (AUC=5).

4.3 Local treatment (surgery, SBRT, ablation, particle or D-BACE treatment): After 3 cycles of D-BACE combined with chemotherapy and camrelizumab, PET-CT and contrast-enhanced brain MRI are performed. The subsequent treatment strategy is evaluated by a multidisciplinary team. If surgical resection is considered feasible, the specific surgical plan is determined by the surgeon. Accepted types of resection (negative margin) include lobectomy, sleeve lobectomy, bilateral lobectomy, or pneumonectomy. If the lesion cannot be completely resected or the patient cannot tolerate surgery after treatment, the radiotherapy and interventional departments will evaluate local radiotherapy, ablation, brachytherapy seeds, or D-BACE as alternative treatment options.

4.4 Adjuvant therapy after local treatment: For this study, adjuvant therapy after local treatment is determined by the investigator. The main regimens include standard 3-4 cycles of adjuvant chemotherapy or immunotherapy maintenance.

4.5 Follow-up Each subject will be monitored for adverse events for at least 30 days after the end of treatment (serious adverse events will be collected for a maximum of 90 days after the end of treatment). Tumor assessments must continue according to the protocol, and the subject will undergo post-treatment follow-up for disease status until one of the following events occurs: (1) disease progression; (2) initiation of non-investigational cancer treatment; (3) withdrawal of consent; (4) loss of follow-up; or (5) death. Before treatment, after neoadjuvant therapy, and after surgery, lung cancer early screening (SHOX2/RASSF1A/PTGER4 gene methylation detection), CAC detection, and MRD detection (at the patient's own expense) will be performed. PBMC blood tests will be completed before treatment and before neoadjuvant therapy. Evaluation is performed by computed tomography (CT) of the chest and total abdomen (with intravenous contrast enhancement, including the liver and adrenal glands and sites of suspected/known disease). Imaging evaluation is performed before each interventional embolization procedure. Postoperative baseline imaging is performed 3 months after local treatment, and then every 12 weeks (±7 days) for up to 2 years, with primary chest (contrast-enhanced) CT. It is recommended to perform head contrast-enhanced MR at least once a year. If obvious neurological symptoms occur, head contrast-enhanced MR should be performed promptly. Whole-body PET-CT is recommended once in the second postoperative year.

4.6 Postoperative Radiotherapy Postoperative radiotherapy (PORT) will be administered at the discretion of the treating oncologist according to standard of care. Based on current international and domestic phase III randomized controlled trials of postoperative radiotherapy, postoperative adjuvant radiotherapy is not routinely performed for patients with complete resection. For patients with non-R0 resection, postoperative adjuvant radiotherapy is not recommended.

4.7 Definition of end of study The start of the trial is defined as the first visit of the first subject. After 3 cycles of D-BACE combined with chemotherapy and camrelizumab, local intervention is performed within 6 weeks after assessment by imaging PET-CT and brain contrast-enhanced MRI, and subsequent adjuvant therapy is determined by the investigator. Survival follow-up continues for 5 years. The study is closed once survival follow-up is completed.

03

Conditions studied

  • NSCLC (Non-small Cell Lung Cancer)

Keywords

  • Drug-eluting beads bronchial arterial chemoembolization
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Only patients who meet all of the following criteria are eligible for inclusion in this study:

Provide written Male or female, aged 18 to 75 years (ECOG) performance status ≤1 in accordance with version 1.1

Subjects must be able to provide a specimen containing tumor tissue or have a newly resected tumor sample available for immunohistochemistry (IHC) testing at a central laboratory during the screening phase:

Before treatment, formalin-fixed, paraffin-embedded (FFPE) tissue blocks or unstained tumor tissue sections and relevant pathology reports must be submitted for biomarker assessment. Tumor tissue specimens may be fresh or archived within 6 months before enrollment.

The tissue must be a core needle biopsy section, excisional biopsy section, or incisional biopsy section.

It is recommended that fresh paraffin sections (PD-L1 assay to be performed within 7 days of sectioning) be stored and transported in the dark.

It is recommended that fresh tissue be fixed in 10% neutral buffered formalin for 24 to 48 hours.

The patient's lung function or other organ function must be evaluated by a surgeon as adequate to tolerate local surgical treatment.

Adequate organ function assessment and laboratory screening must be performed within 7 days prior to initiation of therapy.

Reproductive status:

Women of must have a negative pregnancy test (serum or urine) within 72 hours before the start of treatment.

Women must be non-lactating. Female patients must use appropriate during treatment and for 6 months after the last dose of treatment.

Male subjects must agree to use appropriate contraception during treatment and for 7 months after the last dose of treatment, and must be willing to avoid donating sperm during this period.

Exclusion criteria

Exclusion Criteria:

Medical conditions Stage I, IIIB/IIIC (N3), and stage IV NSCLC. Patients with previous (ICI) immunotherapy, targeted therapy, chemotherapy, or other systemic antitumor therapies.

Patients with . Patients with allergy to contrast media. Patients whose tumors have targeted alterations in EGFR and/or ALK, or known targeted alterations in ROS1, BRAF, , NTRK, MET, or RET. Patients with K-RAS mutations are eligible.

Active known or suspected disease. Subjects are eligible if they have type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, skin conditions (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or other conditions not expected to recur in the absence of an external trigger.

Patients with active (positive hepatitis B surface antigen [HBsAg] test) or (positive HCV RNA test). Patients with previous HBV infection or resolved HBV infection (defined as positive hepatitis B core antibody [HBcAb] and negative HBsAg) are eligible to participate; these patients must provide HBV DNA test results before enrollment. Patients who are HBV carriers or require antiviral therapy are not eligible. Patients who test positive for HCV antibodies are eligible only if they have negative HCV RNA by PCR.

Patients with a history of (HIV) positivity or acquired immunodeficiency syndrome (AIDS).

Any history of arterial thrombosis within 6 months. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months.

Uncontrolled angina, arrhythmia, or congestive heart failure. Other active within 5 years (except adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, superficial bladder cancer, prostate cancer, or breast carcinoma in situ).

Patients with to local treatment (including surgery or intervention) as judged by the investigator.

Serious or uncontrolled medical illness. Patients with psychosis or other conditions resulting in treatment nonadherence.

History of severe reactions to other monoclonal antibodies. Patients who are unwilling to sign the form. Patients who are unwilling to undergo follow-up. Physical and laboratory examinations

Laboratory screening values must not meet any of the following criteria ( version 5.0 applies):

Bone marrow function:

White blood cell count \< 2,000/μL \< 1,500/μL count \< 100 × 10³/μL \< 9.0 g/dL

Liver function:

Serum total > 1.5 times the (ULN) In the presence of liver , and ALT > 5 × ULN, and total bilirubin > 1.5 × ULN

Coagulation function:

Abnormal coagulation function defined as (INR) or prothrombin time (PT) > 1.5 × ULN; if the subject is receiving anticoagulant therapy, PT must be outside the intended therapeutic range of the anticoagulant drug.

Renal function:

Urine protein > 2+, or 24-hour urinary protein ≥ 1 g Serum creatinine > 1.5 × ULN, or calculated (CrCl) \< 50 mL/min (using the Cockcroft-Gault formula) Female CrCl = ([140 - age] × weight [kg] × 0.85) / (72 × serum creatinine [mg/dL]) Male CrCl = ([140 - age] × weight [kg] × 1.00) / (72 × serum creatinine [mg/dL]) Allergy and drug hypersensitivity History of hypersensitivity to other monoclonal antibodies. History of allergic or hypersensitivity reactions to components of the study drugs.

Other exclusion criteria Prisoners or subjects under compulsory confinement. Subjects involuntarily detained for treatment of mental or physical illness (e.g., infectious disease).

Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    D-BACE in combination with chemotherapy and karelizumab

    3 cycles of D-BACE (DCB drug-eluting microspheres loaded with epirubicin 50 mg) in combination with chemotherapy and camrelizumab (the specific chemotherapy regimen is determined by the investigator, and platinum-based doublet chemotherapy is generally used).

    Combination Product: D-BACE in combination with chemotherapy and karelizumab

Interventions

  • Combination productD-BACE in combination with chemotherapy and karelizumab

    D-BACE (drug-eluting bead bronchial arterial chemoembolization) using the watershed vascular embolization concept: 3 cycles of D-BACE with 300-500 μm DC Bead microspheres loaded with epirubicin 50 mg, administered via superselective transarterial chemoembolization of the tumor-feeding watershed vessels. The procedure emphasizes layered and zonal embolization of core and peripheral watershed arteries under digital subtraction angiography (DSA) guidance, with dynamic endpoint assessment using the "near-stasis" criterion. D-BACE is followed within 7 days by camrelizumab (a PD-1 inhibitor) and platinum-based doublet chemotherapy (e.g., pemetrexed plus carboplatin for non-squamous NSCLC, or albumin-bound paclitaxel plus carboplatin), with the specific regimen determined by the investigator. This neoadjuvant combination is evaluated in a Simon two-stage design with major pathological response (MPR) as the primary endpoint.

06

What researchers measure

Primary outcomes

  1. Evaluation of the MPR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Evaluation of the major pathological response (MPR), defined as no more than 10% residual viable tumor cells in the primary tumor bed upon comprehensive pathological assessment, of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Time frame: From enrollment to surgery and pathological assessment, up to approximately 6 months

Secondary outcomes

  1. Evaluation of the pCR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Evaluation of the pathological complete response (pCR), defined as absence of residual viable tumor cells in the primary tumor bed and all sampled lymph nodes upon comprehensive pathological assessment, of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Time frame: From enrollment to surgery and pathological assessment, up to approximately 6 months

  2. Evaluation of the ORR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Evaluation of the objective response rate (ORR) based on RECIST version 1.1 of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Time frame: From enrollment to disease progression or death, assessed every 6 weeks up to 2 years

  3. Evaluation of the EFS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Evaluation of the event-free survival (EFS) in patients who received D-BACE combined with neoadjuvant chemotherapy and camrelizumab. EFS is defined as the time from enrollment to disease progression, local or distant recurrence, second primary malignancy, or death from any cause, whichever occurs first

    Time frame: From enrollment to documented event or censoring, up to 5 years

  4. Evaluation of the PFS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Evaluation of the progression-free survival (PFS) of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab. PFS is defined as the time from enrollment to disease progression per RECIST v1.1 or death from any cause, whichever occurs first

    Time frame: From enrollment to documented progression or death, up to 5 years

  5. Evaluation of the OS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Evaluation of the overall survival (OS) of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab. OS is defined as the time from enrollment to death from any cause

    Time frame: From enrollment to death or censoring, up to 5 years

  6. Evaluation of the safety and tolerability of D-BACE in combination with chemotherapy and camrelizumab in resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC

    Evaluation of the safety and tolerability profile, including perioperative adverse events, intraoperative safety assessment, and postoperative complications, of D-BACE combined with chemotherapy and camrelizumab in resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC, assessed by the incidence, severity, and type of adverse events (AEs) and serious adverse events (SAEs) graded according to NCI CTCAE version 5.0

    Time frame: From enrollment to 30 days after the last dose of study treatment (up to 90 days for serious adverse events)

Other outcomes

  1. Exploration of predictive biomarkers for efficacy and recurrence monitoring via dynamic multi-omics analysis

    Exploration of biomarkers predictive of treatment efficacy and subsequent recurrence monitoring through dynamic multi-omics analysis in individual patients with resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and camrelizumab

    Time frame: From enrollment to disease progression, death, or end of study, up to 5 years

  2. Correlation of radiological and pathological response with PFS and OS

    Assessment of the correlation between radiological response (per RECIST v1.1), pathological response (MPR/pCR), and overall progression-free survival (PFS) as well as overall survival (OS) in patients treated with D-BACE in combination with chemotherapy and camrelizumab

    Time frame: From enrollment to death or censoring, up to 5 years

  3. Immune microenvironment changes assessed by immunohistochemistry and multi-omics analysis

    Density of predefined tumor-infiltrating immune cell subsets (e.g., CD3+, CD8+, CD4+, FOXP3+ regulatory T cells, CD20+ B cells, CD68+ macrophages) will be assessed by immunohistochemistry and multiplex immunofluorescence on paired tumor specimens obtained at baseline (pre-treatment biopsy) and at post-neoadjuvant surgical resection. For each marker, positively stained cells will be counted in predefined tumor and stromal regions of interest using automated image analysis. Each cell subset is reported separately as the mean cell density, expressed as cells per square millimeter (cells/mm²). Change from baseline will be reported as the mean paired difference in cells/mm² with its 95% confidence interval. No aggregation across markers is performed.

    Time frame: From baseline (pre-treatment) to post-neoadjuvant surgery, up to approximately 6 months

  4. Multidimensional evaluation of the watershed vascular embolization concept in D-BACE for NSCLC

    Technical success is defined as successful superselective catheterization and embolization of all planned tumor-feeding arteries within the predefined watershed territory in a single session, without technical failure or need for repeat procedure. Technical success will be adjudicated by two interventional radiologists, with discordant cases resolved by consensus. The reported value is the percentage of participants achieving technical success.

    Time frame: From first D-BACE procedure to postoperative assessment, up to approximately 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest. Data or samples shared will be coded. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.

Supporting information: Study protocol

Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis

Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact cuiwei@gdph.org.cn

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 36 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Jun 11, 2025
StartActual
Dec 22, 2024
Primary completionEst.
Dec 22, 2027
CompletionEst.
Dec 22, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
70→46
Oct 26, 2026
Eligibility
9 inclusion criteria edited, 3 added, 3 removed; 11 exclusion criteria edited, 5 added, 4 removed
What changed in the criteria
Inclusion criteria
  • EditedOnly patients who metmeet all of the following criteria wereare eligible for inclusion in thethis study:
  • AddedProvide written informed consent Male or female, aged 18 to 75 years Eastern Cooperative Oncology Group (ECOG) performance status ≤1 Measurable disease in accordance with RECIST version 1.1
  • EditedProvide written informed consent Male or female, aged 18-75 years Eastern Cooperative Oncology Group performance status ≤1 Measurable lesions in accordance with RECIST, version 1.1 Subjects must be able to provide a specimen containing tumor tissue or have a biopsy sample of newly resected tumor tissuebiopsy sample available for PD-L1 immunohistochemistry (IHC) testing was performed at a central laboratory during the screening phase:
  • EditedBefore treatment, formalin-fixed, paraffin-embedded (FFPE) tissue blocks or non-stainedunstained tumor tissue sections and relevant pathology reports must be submitted for biomarker assessment. Tumor- tissue specimens couldmay be fresh or archived within 6 months before enrollment.
  • EditedThe tissue must be a core needle biopsy section, excisional biopsy section, or openincisional biopsy section;.
  • EditedIt is recommended that fresh paraffin sections (PD-L1 assaysassay to be performed within 7 days of sectioning) slides be stored and transported in the dark.
  • EditedIt is recommended that fresh tissue be fixed in 10% neutral buffered formalin for 24 to 48 hours The patient's lung function or other organ function was evaluated by the surgeon to tolerate local surgical treatment.
  • AddedThe patient's lung function or other organ function must be evaluated by a surgeon as adequate to tolerate local surgical treatment.
  • EditedAdequate organ function assessment and laboratory screening shouldmust be performed within 7 days ofprior to initiation of therapy.
  • EditedAWomen of childbearing potential must have a negative pregnancy test (serum or urine) in a woman of childbearing age within 72 hours before the start of treatment.
  • Removedwomen were non-lactating
  • RemovedFor female patients, appropriate contraception should be used during treatment and for 6 months after the last dose of treatment (i.e., the time required for the 30-day ovulation cycle + the 5 half-lives of the drug).
  • AddedWomen must be non-lactating. Female patients must use appropriate contraception during treatment and for 6 months after the last dose of treatment.
  • EditedMale subjects must agree to use appropriate contraception during treatment and for 7 months after the last dose of treatment (i.e., the duration of 90-dayand must be willing to avoid donating sperm turnover + 5 half-lives of the drug)during this period.
  • RemovedAnd male subjects had to be willing to avoid donating sperm during this period.
Exclusion criteria
  • EditedMedical conditions Stage I, IIIB/IIIC (N3), and stage IV NSCLC patients. Patients with previous ICIsimmune checkpoint inhibitor (ICI) immunotherapy, targeted therapy, chemotherapy, andor other systemic antitumor therapies were excluded.
  • EditedPatients with brain metastases. Patients with allergy to contrast media were not eligible. Patients were excluded if theirwhose tumors hadhave targeted alterations in EGFR and/or ALK, or were known to have targeted alterations in ROS1, BRAF, HER-2, NTRK, MET, or RET. Patients with K-RAS mutations could be enrolledare eligible.
  • EditedActive known or suspected autoimmune disease Participants were. Subjects are eligible if they hadhave type I1 diabetes, hypothyroidism requiring only hormone- replacement therapy, skin conditions (e.g., vitiligo, psoriasis, or alopecia) that did not requirerequiring systemic treatment, or other conditions that were not expected to recistrecur in the absence of an external trigger.
  • EditedPatients with active hepatitis B (positive hepatitis B surface antigen [HBsAg] test) or hepatitis C (positive HCV RNA test). Patients with previous HBV infection or a decommissionedresolved HBV infection (defined as positive for the hepatitis B core antibody [HBcAb] and negative for HBsAg) wereare eligible to participate. Patients were required to; these patients must provide HBV DNA test results before enrollment, and participants. Patients who wereare HBV carriers or requiredrequire antiviral therapy wereare not eligible. Patients who testedtest positive for HCV antibodies could participate in the studyare eligible only if they hadhave negative PCR results for HCV RNA by PCR.
  • AddedPatients with a history of human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS).
  • AddedAny history of arterial thrombosis within 6 months. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months.
  • EditedAny history of arterial thrombosis within 6 months of human immunodeficiency virus (HIV) -positive or acquired immunodeficiency syndrome (AIDS), History of deep vein thrombosis, pulmonary embolism, or any other major thromboembolism within 3 months uncontrolledUncontrolled angina, arrhythmia, or congestive heart failure. Other active malignancy within 5 years other active malignancy (except adequately treated carcinoma in situ of the cervix or, basal cell or squamous cell skin cancer, superficial bladder cancer, or prostate cancer, or breast cancercarcinoma in situ) Patients with contraindications to local treatment (including surgery or intervention) as judged by the investigator.
  • AddedPatients with contraindications to local treatment (including surgery or intervention) as judged by the investigator.
  • AddedSerious or uncontrolled medical illness. Patients with psychosis or other conditions resulting in treatment nonadherence.
  • EditedSerious or uncontrolled medical illness The patient has psychosis or other medical conditions that result in treatment nonadherence History of severe hypersensitivity reactions to other monoclonal antibodies. Patients who are unwilling to sign the informed consent formsform. Patients who do not wantare unwilling to undergo follow-up. Physical and laboratory tests Laboratory screening values must exclude the following criteria (CTCAE version 5 applies)examinations
  • AddedLaboratory screening values must not meet any of the following criteria (CTCAE version 5.0 applies):
  • EditedWhite blood cell count < 20002,000/uL, neutrophilμL Neutrophil count < 15001,500/uL, plateletμL Platelet count < 100 ×103 10³/Ul, hemoglobinμL Hemoglobin < 9.0g0 g/dL
  • RemovedSerum total bilirubin > 1.5 times the upper limit of normal value (ULN);
  • EditedSerum total bilirubin > 1.5 times the upper limit of normal (ULN) In the casepresence of liver metastases, AST and ALT were > 5 × ULN, and total bilirubin > 1.5ULN5 × ULN
  • EditedAbnormal coagulation function was defined as international normalized ratio (INR) or prothrombin time (PT) > 1.5 times× ULN; Ifif the subject wasis receiving anticoagulant therapy, PT wasmust be outside the intended usetherapeutic range of the anticoagulant drugsdrug.
  • EditedUrinaryUrine protein > 2+, or 24-hour urinary protein ≥1g; 1 g Serum creatinine > 1.5 × ULN, or calculated creatinine clearance (CrCl) < 50ml50 mL/min (using the Cockcroft-Gault formula) Female CrCLCrCl = ([140 - age] × weight ([kg)] × 0.85) / (72 × serum creatinine ([mg/dL]) Male CrCLCrCl = ([140 - age] × weight ([kg)] × 1.00) / (72 × serum creatinine ([mg/dL]) Allergy and adverse drug reactions 1) A historyhypersensitivity History of hypersensitivity to other monoclonal antibodies 2) A history. History of allergic or hypersensitivehypersensitivity reactions to the components of the study drug Other exclusion criteriadrugs.
  • RemovedPrisoners or subjects under compulsory confinement.
  • EditedOther exclusion criteria Prisoners or subjects who have beenunder compulsory confinement. Subjects involuntarily detained for treatment of mental or physical illness (e.g., infectious disease).
  • RemovedCareful consideration has been given to the eligibility criteria for this study to ensure the safety of the study subjects and to ensure the availability of the study results.
  • Removed-
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedEvaluation of the pCRMPR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to surgery and pathological assessment, up to approximately 6 months
Oct 26, 2026
Secondary outcomes
7 edited, 3 added, 2 removed
What changed in the outcomes
  • EditedEvaluation of the MPRpCR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to surgery and pathological assessment, up to approximately 6 months
  • EditedEvaluation of the ORR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to disease progression or death, assessed every 6 weeks up to 2 years
  • EditedEvaluation of the EFS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to documented event or censoring, up to 5 years
  • EditedEvaluation of the PFS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to documented progression or death, up to 5 years
  • EditedEvaluation of the OS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to death or censoring, up to 5 years
  • EditedEvaluation as assessed by CTCAE v4.0 of the safety and tolerability of D-BACE in combination with chemotherapy and camrelizumab in resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to 30 days after the last dose of study treatment (up to 90 days for serious adverse events)
  • Editedother outcomeThe correlationCorrelation of imaging responseradiological and pathological response with overall PFS and OS was observed and evaluated.Time frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to death or censoring, up to 5 years
  • Addedother outcomeExploration of predictive biomarkers for efficacy and recurrence monitoring via dynamic multi-omics analysisTime frame: From enrollment to disease progression, death, or end of study, up to 5 years
  • Addedother outcomeImmune microenvironment changes assessed by immunohistochemistry and multi-omics analysisTime frame: From baseline (pre-treatment) to post-neoadjuvant surgery, up to approximately 6 months
  • Addedother outcomeMultidimensional evaluation of the watershed vascular embolization concept in D-BACE for NSCLCTime frame: From first D-BACE procedure to postoperative assessment, up to approximately 6 months
  • Removedother outcomeBiomarkers (T-cell subsets) for predicting the efficacy (PFS and OS) of new D-BACE combined with chemotherapy and camrelizumab treatment and subsequent recurrence monitoring were exploredTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day)
  • Removedother outcomeChanges in the infiltrating immune microenvironmentTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day)
Oct 26, 2026
Title
D-BACE in Combination With Chemotherapy and CarelizumabCamrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Oct 26, 2026
Design
Phase 3→Phase 2
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Enrollment 70→46
    Eligibility 9 inclusion criteria edited, 3 added, 3 removed; 11 exclusion criteria edited, 5 added, 4 removed
    What changed in the criteria
    Inclusion criteria
    • EditedOnly patients who metmeet all of the following criteria wereare eligible for inclusion in thethis study:
    • AddedProvide written informed consent Male or female, aged 18 to 75 years Eastern Cooperative Oncology Group (ECOG) performance status ≤1 Measurable disease in accordance with RECIST version 1.1
    • EditedProvide written informed consent Male or female, aged 18-75 years Eastern Cooperative Oncology Group performance status ≤1 Measurable lesions in accordance with RECIST, version 1.1 Subjects must be able to provide a specimen containing tumor tissue or have a biopsy sample of newly resected tumor tissuebiopsy sample available for PD-L1 immunohistochemistry (IHC) testing was performed at a central laboratory during the screening phase:
    • EditedBefore treatment, formalin-fixed, paraffin-embedded (FFPE) tissue blocks or non-stainedunstained tumor tissue sections and relevant pathology reports must be submitted for biomarker assessment. Tumor- tissue specimens couldmay be fresh or archived within 6 months before enrollment.
    • EditedThe tissue must be a core needle biopsy section, excisional biopsy section, or openincisional biopsy section;.
    • EditedIt is recommended that fresh paraffin sections (PD-L1 assaysassay to be performed within 7 days of sectioning) slides be stored and transported in the dark.
    • EditedIt is recommended that fresh tissue be fixed in 10% neutral buffered formalin for 24 to 48 hours The patient's lung function or other organ function was evaluated by the surgeon to tolerate local surgical treatment.
    • AddedThe patient's lung function or other organ function must be evaluated by a surgeon as adequate to tolerate local surgical treatment.
    • EditedAdequate organ function assessment and laboratory screening shouldmust be performed within 7 days ofprior to initiation of therapy.
    • EditedAWomen of childbearing potential must have a negative pregnancy test (serum or urine) in a woman of childbearing age within 72 hours before the start of treatment.
    • Removedwomen were non-lactating
    • RemovedFor female patients, appropriate contraception should be used during treatment and for 6 months after the last dose of treatment (i.e., the time required for the 30-day ovulation cycle + the 5 half-lives of the drug).
    • AddedWomen must be non-lactating. Female patients must use appropriate contraception during treatment and for 6 months after the last dose of treatment.
    • EditedMale subjects must agree to use appropriate contraception during treatment and for 7 months after the last dose of treatment (i.e., the duration of 90-dayand must be willing to avoid donating sperm turnover + 5 half-lives of the drug)during this period.
    • RemovedAnd male subjects had to be willing to avoid donating sperm during this period.
    Exclusion criteria
    • EditedMedical conditions Stage I, IIIB/IIIC (N3), and stage IV NSCLC patients. Patients with previous ICIsimmune checkpoint inhibitor (ICI) immunotherapy, targeted therapy, chemotherapy, andor other systemic antitumor therapies were excluded.
    • EditedPatients with brain metastases. Patients with allergy to contrast media were not eligible. Patients were excluded if theirwhose tumors hadhave targeted alterations in EGFR and/or ALK, or were known to have targeted alterations in ROS1, BRAF, HER-2, NTRK, MET, or RET. Patients with K-RAS mutations could be enrolledare eligible.
    • EditedActive known or suspected autoimmune disease Participants were. Subjects are eligible if they hadhave type I1 diabetes, hypothyroidism requiring only hormone- replacement therapy, skin conditions (e.g., vitiligo, psoriasis, or alopecia) that did not requirerequiring systemic treatment, or other conditions that were not expected to recistrecur in the absence of an external trigger.
    • EditedPatients with active hepatitis B (positive hepatitis B surface antigen [HBsAg] test) or hepatitis C (positive HCV RNA test). Patients with previous HBV infection or a decommissionedresolved HBV infection (defined as positive for the hepatitis B core antibody [HBcAb] and negative for HBsAg) wereare eligible to participate. Patients were required to; these patients must provide HBV DNA test results before enrollment, and participants. Patients who wereare HBV carriers or requiredrequire antiviral therapy wereare not eligible. Patients who testedtest positive for HCV antibodies could participate in the studyare eligible only if they hadhave negative PCR results for HCV RNA by PCR.
    • AddedPatients with a history of human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS).
    • AddedAny history of arterial thrombosis within 6 months. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months.
    • EditedAny history of arterial thrombosis within 6 months of human immunodeficiency virus (HIV) -positive or acquired immunodeficiency syndrome (AIDS), History of deep vein thrombosis, pulmonary embolism, or any other major thromboembolism within 3 months uncontrolledUncontrolled angina, arrhythmia, or congestive heart failure. Other active malignancy within 5 years other active malignancy (except adequately treated carcinoma in situ of the cervix or, basal cell or squamous cell skin cancer, superficial bladder cancer, or prostate cancer, or breast cancercarcinoma in situ) Patients with contraindications to local treatment (including surgery or intervention) as judged by the investigator.
    • AddedPatients with contraindications to local treatment (including surgery or intervention) as judged by the investigator.
    • AddedSerious or uncontrolled medical illness. Patients with psychosis or other conditions resulting in treatment nonadherence.
    • EditedSerious or uncontrolled medical illness The patient has psychosis or other medical conditions that result in treatment nonadherence History of severe hypersensitivity reactions to other monoclonal antibodies. Patients who are unwilling to sign the informed consent formsform. Patients who do not wantare unwilling to undergo follow-up. Physical and laboratory tests Laboratory screening values must exclude the following criteria (CTCAE version 5 applies)examinations
    • AddedLaboratory screening values must not meet any of the following criteria (CTCAE version 5.0 applies):
    • EditedWhite blood cell count < 20002,000/uL, neutrophilμL Neutrophil count < 15001,500/uL, plateletμL Platelet count < 100 ×103 10³/Ul, hemoglobinμL Hemoglobin < 9.0g0 g/dL
    • RemovedSerum total bilirubin > 1.5 times the upper limit of normal value (ULN);
    • EditedSerum total bilirubin > 1.5 times the upper limit of normal (ULN) In the casepresence of liver metastases, AST and ALT were > 5 × ULN, and total bilirubin > 1.5ULN5 × ULN
    • EditedAbnormal coagulation function was defined as international normalized ratio (INR) or prothrombin time (PT) > 1.5 times× ULN; Ifif the subject wasis receiving anticoagulant therapy, PT wasmust be outside the intended usetherapeutic range of the anticoagulant drugsdrug.
    • EditedUrinaryUrine protein > 2+, or 24-hour urinary protein ≥1g; 1 g Serum creatinine > 1.5 × ULN, or calculated creatinine clearance (CrCl) < 50ml50 mL/min (using the Cockcroft-Gault formula) Female CrCLCrCl = ([140 - age] × weight ([kg)] × 0.85) / (72 × serum creatinine ([mg/dL]) Male CrCLCrCl = ([140 - age] × weight ([kg)] × 1.00) / (72 × serum creatinine ([mg/dL]) Allergy and adverse drug reactions 1) A historyhypersensitivity History of hypersensitivity to other monoclonal antibodies 2) A history. History of allergic or hypersensitivehypersensitivity reactions to the components of the study drug Other exclusion criteriadrugs.
    • RemovedPrisoners or subjects under compulsory confinement.
    • EditedOther exclusion criteria Prisoners or subjects who have beenunder compulsory confinement. Subjects involuntarily detained for treatment of mental or physical illness (e.g., infectious disease).
    • RemovedCareful consideration has been given to the eligibility criteria for this study to ensure the safety of the study subjects and to ensure the availability of the study results.
    • Removed-
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedEvaluation of the pCRMPR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to surgery and pathological assessment, up to approximately 6 months
    Secondary outcomes 7 edited, 3 added, 2 removed
    What changed in the outcomes
    • EditedEvaluation of the MPRpCR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to surgery and pathological assessment, up to approximately 6 months
    • EditedEvaluation of the ORR of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to disease progression or death, assessed every 6 weeks up to 2 years
    • EditedEvaluation of the EFS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to documented event or censoring, up to 5 years
    • EditedEvaluation of the PFS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to documented progression or death, up to 5 years
    • EditedEvaluation of the OS of resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabcamrelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to death or censoring, up to 5 years
    • EditedEvaluation as assessed by CTCAE v4.0 of the safety and tolerability of D-BACE in combination with chemotherapy and camrelizumab in resectable II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC treated with D-BACE in combination with chemotherapy and karelizumabTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to 30 days after the last dose of study treatment (up to 90 days for serious adverse events)
    • Editedother outcomeThe correlationCorrelation of imaging responseradiological and pathological response with overall PFS and OS was observed and evaluated.Time frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day) → From enrollment to death or censoring, up to 5 years
    • Addedother outcomeExploration of predictive biomarkers for efficacy and recurrence monitoring via dynamic multi-omics analysisTime frame: From enrollment to disease progression, death, or end of study, up to 5 years
    • Addedother outcomeImmune microenvironment changes assessed by immunohistochemistry and multi-omics analysisTime frame: From baseline (pre-treatment) to post-neoadjuvant surgery, up to approximately 6 months
    • Addedother outcomeMultidimensional evaluation of the watershed vascular embolization concept in D-BACE for NSCLCTime frame: From first D-BACE procedure to postoperative assessment, up to approximately 6 months
    • Removedother outcomeBiomarkers (T-cell subsets) for predicting the efficacy (PFS and OS) of new D-BACE combined with chemotherapy and camrelizumab treatment and subsequent recurrence monitoring were exploredTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day)
    • Removedother outcomeChanges in the infiltrating immune microenvironmentTime frame: From enrollment to the end of treatment at 3 cycle (1 cycle is 21 day)
    Design Phase 3→Phase 2
    Title D-BACE in Combination With Chemotherapy and CarelizumabCamrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
    + 5 other changes: index terms, verification date, oversight details, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07016126
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Dec 22, 2024
Primary completion
Dec 22, 2027 (estimated)
Completion
Dec 22, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Wei Cui, Dr
Contact
cuiwei@gdph.org.cn
86 15626430801

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion